Biotech

All Articles

AstraZeneca articles information on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early check out the efficiency of its own in-house antibo...

iTeos- GSK's TIGIT star presents significant renovation

.After introducing a stage 3 launch based upon beneficial midstage end results, iTeos as well as GSK...

More collaborative FDA can easily increase unusual disease R&ampD: record

.The FDA ought to be a lot more open as well as joint to discharge a surge in commendations of uncom...

Zenas, MBX, Bicara head to Nasdaq in scorching day for biotech IPOs

.It is actually an unusually occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara ...

Atea's COVID antiviral stops working to halt hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has stopped working yet another COVID-19 trial, yet the biotech sti...

Neurocrine's offer to save mental illness prospect stops working

.Neurocrine Biosciences' mental illness system pivot has actually fallen short. The biotech was actu...

Sanofi pays for $110M upfront for late-stage radioligand treatment

.Sanofi has made an overdue entry to the radioligand gathering, spending one hundred million euros (...

F 2G increases $100M for 2nd attempt to get brand new antifungal to market

.After F2G's very first try to get a new course of antifungal to market was actually wrecked due to ...

Moderna targets $1.1 B in R&ampD investing cuts, drops 5 plans in the middle of earnings pressures

.Moderna has actually promised to cut R&ampD investing by $1.1 billion by 2027. The selection to shr...

Sanofi's $80M bank on Fulcrum dystrophy medication ends in phase 3 crash

.Simply four months after Sanofi wager $80 million in upfront cash on Pivot Rehabs' losmapimod, the ...